Rosuvastatin Calcium (cas 147098-20-2)
Indications: Adjuvant treatment for patients with primary hypercholesterolemia (typeaa, including heterozygous familial hypercholesterolemia) or mixed lipoproteinemia (typeⅡb) when diet or exercise therapy is not ideal.(Hypolipidemia)
Pharmacology: Inhibit HMG-CoA reductase, reduce liver cell synthesis and storage of cholesterol, thereby reducing total blood cholesterol (TC) and LDL cholesterol
Compound Information Table: Rosuvastatin Calcium
| Category | Details |
|---|---|
| Name | Rosuvastatin Calcium |
| CAS Number | 147098-20-2 |
| Synonyms | CRESTOR; ROSUVASTATIN CA; ROSUVASTATIN CALCIUM; (3R,5S,6E)-7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[N-methyl(n-methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-6-heptenoic acid calcium salt |
| EINECS Number | 627-028-1 |
| Molecular Formula | C₄₄H₅₄CaF₂N₆O₁₂S₂ |
| Molecular Weight | 1001.14 g/mol |
| Chemical Properties | |
| – Appearance | White to Off-White Crystalline Solid |
| – Melting Point | 122°C |
| – Optical Activity | [α]/D +12 to +18° (c = 1 in methanol:water, 1:1) |
| – Storage Temp. | 2–8°C |
| – Solubility | DMSO (25 mg/mL, requires ultrasonic treatment); Water (1 mg/mL, requires ultrasonic treatment) |
| – Form | Powder |
| – Color | White to Beige |
| InChIKey | JSVIQRTVYKCCOM-LMRKSJJTNA-N |
Key Notes:
- Pharmacological Role:
- A competitive HMG-CoA reductase inhibitor, primarily used to lower LDL cholesterol and triglycerides.
- Exhibits dual-channel metabolism (10% hepatic CYP450 metabolism, 90% renal excretion), reducing drug interaction risks 1.
- Clinical Applications:
- Approved Indications:
- Hypercholesterolemia (familial and non-familial).
- Mixed dyslipidemia.
- Cardiovascular disease prevention (e.g., post-myocardial infarction).
- Dosage: 5–40 mg/day, adjusted for renal/hepatic impairment 5.
- Approved Indications:
- Safety & Toxicity:
- Common Side Effects: Myalgia, headache, nausea, elevated liver enzymes.
- Severe Risks: Rhabdomyolysis (rare), hepatotoxicity, new-onset diabetes.
- Handling & Stability:
- Store in a dry, dark environment (2–8°C).
- Avoid prolonged exposure to light or moisture.
Analytical & Formulation Guidelines:
- Detection: UV-Vis spectroscopy (λmax = 243 nm in phosphate buffer).
- Stability: Stable under refrigeration; avoid freeze-thaw cycles.
For spectral data (InChIKey: JSVIQRTVYKCCOM-LMRKSJJTNA-N) or pharmacokinetic studies, consult PubChem
sale@pharma-peptides.com
请到「后台-用户-个人资料」中填写个人说明。